SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders
Retrieved on:
Monday, June 7, 2021
Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.
Key Points:
- Shareholder rights law firm Robbins LLP is investigating Athenex, Inc. (NASDAQ: ATNX) to determine whether certain Athenex officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company.
- Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next generation drugs for the treatment of cancer.
- One of the Company's main drug candidates is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
- Robbins LLP is a nationally recognized leader in shareholder rights law.